Table 3.
Effects of Niaspan® on atherosclerosis in the ARBITER 2 study and in a pooled analysis of data from the ARBITER 2 and ARBITER 3 studies
| Niaspan® | Placebo | |||
|---|---|---|---|---|
| Mean change in CIMT (mm) | P | Mean change in CIMT (mm) | P | |
| ARBITER2 | 0.014 ± 0.011 | 0.23 | 0.044 ± 0.011 | <0.001 |
| ARBITER 3 | ||||
| Patients switching from placebo to Niaspan® (n = 47) | −0.095 ± 0.019 | <0.001 | – | – |
| Patients continuing on Niaspan® for additional 12 months (n = 57) | −0.041 + 0.021 | 0.001 | – | – |
| Pooled analysis of ARBITER 2 and ARBITER 3 | ||||
| First 12 months of Niaspan® in ARBITER 2 or ARBITER 3 (n = 125) | −0.027 ± 0.011 | <0.001 | – | – |
| 12–24 months of Niaspan® in patients with type 2 diabetes or the metabolic syndrome (n = 62) | −0.046 ± 0.131 | <0.001 | – | – |
Notes: Significance values for ARBITER 2 are relative to baseline, while significance values for ARBITER 3 or the pooled analysis of ARBITER 2 and ARBITER 3 are relative to the placebo phase of ARBITER 2. Compiled from data presented by Taylor et al (2004, 2006).
Abbreviations: CIMT, carotid intima-media thickness.